VG Life Sciences announced the closing of a significant capital event. MedBridge Venture Fund, LLC has made a cash investment in the company of $2,235,000. This is in addition to the $550,000 cash investment made by MedBridge, LLC in March.

This new funding will enable VG Life Sciences to begin and complete many key milestones outlined in the company's July Investor Letter and meet short term capital needs. The invented peptide (VG1177) has a wide range of potential applications, including HIV/AIDS, Preeclampsia, Brain Trauma, Hypertension, Lyme disease, and many more autoimmune and chronic inflammatory disorders.